ArticleFrontiers in pharmacology2025
Calcio-herbal medicine Divya-Swasari-Vati demonstrates acceptable non-clinical safety profile in the repeated-dose 28-day subacute oral toxicity study in Sprague-Dawley rats, under GLP compliance.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanocrystalline Drug Delivery Systems for Natural Compounds: Progress, Challenges and Future Opportunities.International journal of nanomedicine · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ayurvedic medicines with scientifically proven anti-inflammatory, bronchodilator, anti-tussive and anti-microbial activities have an immense potential to be repurposed for the management of obstructive airway symptoms, frequently encountered in patients afflicted with coronavirus disease 2019 (COVID-19). Divya-Swasari-Vati is an Ayurvedic prescription medicine, which contains nine botanical drugs and seven mineral ashes. The individual botanical drugs and minerals present in Divya-Swasari-Vati have been traditionally used for the treatment of upper and lower respiratory tract symptoms, associated with ailments ranging from common cold and cough to chronic asthma and respiratory infections. Divya-Swasari-Vati is enriched with metabolites known to possess pharmacological activity and has demonstrated Methods: This toxicological study was conducted according to Organization for Economic Cooperation and Development (OECD) test guideline 407 and in conformance with the OECD principles of Good Laboratory Practice (GLP). Divya-Swasari-Vati was tested at the doses of 100, 300 and 1,000 mg/kg/day, in five males and five female rats of each experimental group. Results: In the present study, no mortality or morbidity was observed in any of the test groups. Furthermore, Divya-Swasari-Vati treatment was not associated with any toxicologically relevant outcomes with respect to clinical signs as well as clinical-, gross- and histo-pathological findings, as compared to the vehicle-administered group. Consequently, the No-Observed-Adverse-Effect-Level (NOAEL) of Divya-Swasari-Vati was determined to be 1,000 mg/kg/day, in both male and female rats. Discussion: The acceptable safety profile of Divya-Swasari-Vati demonstrated in the present study, provisions for its future non-clinical safety assessments for longer duration in rodents as well as in higher animals. Additionally, this study also serves as the first step towards the detailed assessment of Divya-Swasari-Vati in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.